CTCX CARMELL THERAPEUTICS CORP

Carmell Corporation Launches Skincare Partnership With Ladies Playbook to Support and Celebrate NFL Sports Community

Carmell Corporation Launches Skincare Partnership With Ladies Playbook to Support and Celebrate NFL Sports Community

Carmell provides its revolutionary regenerative skincare through the first of its kind partnership with Ladies Playbook, an exclusive community dedicated to providing support, information, and the connections needed for National Football League (“NFL”) families to thrive.

PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Company” or “Carmell”), today announced a strategic partnership with Ladies Playbook, an exclusive community dedicated to providing support, information, and the connections for an NFL family to thrive wherever their football career takes them.

The NFL is the most valuable sports franchise in the world, with annual revenues approaching $20 billion from 32 teams, collectively worth approximately $160 billion, according to Statista.

This partnership comes as the new NFL season kicks into full gear and as Carmell aims to accelerate the growth of its flagship brand, Carmell Secretome™, through the expansion of its direct-to-consumer and e-commerce customer channels as well as driving toward influential franchise initiatives like Ladies Playbook. Carmell Secretome™ is a new approach to regenerative skincare and haircare that consists of a potent cocktail of proteins, peptides and bio-lipids extracted from allogeneic human platelets without the use of synthetic proteins.

“After spending 11 years in the NFL, I created Ladies Playbook as a space to help other women find all their needs conveniently in one place. Our partnership with Carmell enables NFL Ladies an opportunity to enhance their own skin health through bio-aesthetic derived products and the local MedSpa community,” said Atoya Burleson, Founder of Ladies Playbook.

Through this partnership, Carmell will showcase its commitment to skin health and education by hosting a series of events with key wives and girlfriends from the NFL community in various markets from Seattle, Minnesota, Miami and New York. Furthering its commitment, Carmell and Ladies Playbook will also build omni-channel opportunities to feature both brands across social media, ladiesplaybook.com, carmellsecretome.com and digital platforms leading to the Ladies Playbook Awards in New Orleans – Super Bowl LIX.

“We understand the importance of skin health and its impact on internal systems that are imperative to our overall health and well-being, many of the ambassadors are playing within their homes. The alignment between our brands is rooted in our focus on a revolutionary approach to regenerative skincare that utilizes human biology vs. synthetic chemistry to target the five pathways of skin aging to support skin and hair health. While our technology is impressive, what’s equally impressive is what is not in the bottle. In our goal for Carmell Secretome™ to be the best skincare in the market, we developed a list of 14 excipients that will never be found in our products. We call them The Foul Fourteen™. By excluding these excipients from our products, we ensure our products are just as nature intended and nothing more. From being on the field, to traveling between games, running their own businesses and more, we are excited to provide products to the Ladies Playbook community to support skin health with no harsh chemicals, no pore-clogging goo, no artificial dyes and no fake fragrances,” said Kendra Bracken-Ferguson, Chief Executive Officer of Carmell.

About Carmell

Carmell is a bio-aesthetics company that utilizes the Carmell Secretome™ to support skin and hair health. The Carmell Secretome™ consists of a potent cocktail of proteins, peptides and bio-lipids extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. Over the past seven years, the Company has extensively tested the technology underpinning the Carmell Secretome™. Additionally, the Company has developed a novel microemulsion formulation that enables the delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen™, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. The Company is also developing a line of men’s products and a line of topical haircare products. All products are tailored to meet the demanding technical requirements of professional care providers and discerning retail consumers. For more information, visit .

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs, assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the launch and commercialization of our products, our expected cash runway, our potential acquisition and investment activity, the anticipated benefits of future acquisitions and investments, our projected future results and market opportunities, our expected growth and ability to achieve profitability, the expansion of our product portfolio and the execution of our business strategy. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, those described under the header “Risk Factors” in the Annual Report on Form 10-K filed by Carmell with the SEC on April 1, 2024, as amended by the Annual Report on Form 10-K/A filed with the SEC on April 29, 2024, and in our other reports filed with the SEC. Most of these factors are outside of Carmell’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Except as required by law, we undertake no obligation to publicly update any forward-looking statement contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Contact:

Bryan Cassaday, CFO



EN
05/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CARMELL THERAPEUTICS CORP

 PRESS RELEASE

Longevity Health Holdings Announces Execution of Merger Agreement With...

Longevity Health Holdings Announces Execution of Merger Agreement With 20/20 Biolabs PITTSBURGH, Pa. & GAITHERSBURG, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition (“Longevity”, the “Company”, “we”, “our”, or “us”), today announced the execution of a merger agreement (the “Merger”) with 20/20 BioLabs, Inc. (“20/20”), a leading provider of innovative laboratory tests for t...

 PRESS RELEASE

CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINE...

CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX; CTCXW), a bio-aesthetics company (the “Company”, “we”, “our”, or “us”), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company’s market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to “Longevity Health Holdings, I...

 PRESS RELEASE

Carmell Announces Closing of Elevai Skincare Acquisition

Carmell Announces Closing of Elevai Skincare Acquisition PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of the previously announced acquisition of the skin and hair care business of Elevai Skincare, Inc. (“Elevai”), a leader in physician dispensed exosome skin and hair care products, pursuant to a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) (“PMGC”) and Elevai, its wholly owned subsid...

 PRESS RELEASE

Carmell Announces Closing of Previously Announced PIPE Investment from...

Carmell Announces Closing of Previously Announced PIPE Investment from Existing and New Investors to Support Commercial Build-out PITTSBURGH, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of its previously announced private placement with new and existing investors pursuant to a securities purchase agreement, dated December 23, 2024, for the issuance and sale of 8,065,210 shares of its common stock and an equal number of five-year w...

 PRESS RELEASE

Carmell Announces Execution of Definitive Agreement to Acquire Elevai ...

Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products PITTSBURGH, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) and its wholly owned subsidiary, Elevai Skincare Inc. (“Elevai”), to acquire the assets related to its skincare and haircare business (th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch